(S)-HPMPA

Cat. No.: HY-W565665: Data Sheet Handling Instructions
FAQs
Technical Support

(S)-HPMPA is an antiviral agent. (S)-HPMPA can bind to and interfere with viral DNA polymerase activity, thereby inhibiting viral DNA synthesis. (S)-HPMPA can be used for the study of DNA viruses.

For research use only. We do not sell to patients.

(S)-HPMPA Chemical Structure

CAS No. : 92999-29-6

Size		Stock
MOQ		Minimum order quantity
50 mg		Get quote
100 mg		Get quote
250 mg		Get quote
Other size		Get quote

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Featured Recommendations

•Related Small Molecules:

•Related Proteins:

View All DNA/RNA Synthesis Isoform Specific Products:

View All Isoforms

RNASE L DNA Polymerases RNA Polymerases Helicases DNA Ligase

Biological Activity
Purity & Documentation
References
Customer Review

Description

IC₅₀ & Target

DNA Polymerase

Cellular Effect

Cell Line	Type	Value	Description	References
BSC-1	CC₅₀	89.3 μM Compound: HPMPA	Cytotoxicity against african green monkey BSC1 cells Cytotoxicity against african green monkey BSC1 cells	[PMID: 17420214]
BSC-1	EC₅₀	10.2 μM Compound: HPMPA	Antiviral activity against Simian virus 40 PML2 DAR in african green monkey BSC1 cells assessed as reduction of virus-induced cytopathogenicity Antiviral activity against Simian virus 40 PML2 DAR in african green monkey BSC1 cells assessed as reduction of virus-induced cytopathogenicity	[PMID: 17420214]
BSC-1	EC₅₀	12.3 μM Compound: HPMPA	Antiviral activity against Simian virus 40 A2895 in african green monkey BSC1 cells assessed as reduction of virus-induced cytopathogenicity Antiviral activity against Simian virus 40 A2895 in african green monkey BSC1 cells assessed as reduction of virus-induced cytopathogenicity	[PMID: 17420214]
BSC-1	EC₅₀	15.4 μM Compound: HPMPA	Antiviral activity against Simian virus 40 PML1 EK in african green monkey BSC1 cells assessed as reduction of virus-induced cytopathogenicity Antiviral activity against Simian virus 40 PML1 EK in african green monkey BSC1 cells assessed as reduction of virus-induced cytopathogenicity	[PMID: 17420214]
HEL	EC₅₀	0.036 μM Compound: HPMPA	Antiviral activity against foscarnet-resistant HCMV AD169 clone C infected in HEL cells assessed as inhibition of virus-induced cytopathicity Antiviral activity against foscarnet-resistant HCMV AD169 clone C infected in HEL cells assessed as inhibition of virus-induced cytopathicity	[PMID: 19226140]
HEL	EC₅₀	0.08 μM Compound: HPMPA	Antiviral activity against acyclovir-resistant HCMV AD169 clone 1 infected in HEL cells assessed as inhibition of virus-induced cytopathicity Antiviral activity against acyclovir-resistant HCMV AD169 clone 1 infected in HEL cells assessed as inhibition of virus-induced cytopathicity	[PMID: 19226140]
HEL	EC₅₀	0.081 μg/mL Compound: (S)-HPMPA	Antiviral activity against acyclovir-resistant HCMV with DNA polymerase mutant in HEL cells assessed as reduction of virus-induced cytopathogenicity Antiviral activity against acyclovir-resistant HCMV with DNA polymerase mutant in HEL cells assessed as reduction of virus-induced cytopathogenicity	[PMID: 18707089]
HEL	EC₅₀	0.11 μg/mL Compound: (S)-HPMPA	Antiviral activity against foscarnet-resistant HCMV with DNA polymerase mutant in HEL cells assessed as reduction of virus-induced cytopathogenicity Antiviral activity against foscarnet-resistant HCMV with DNA polymerase mutant in HEL cells assessed as reduction of virus-induced cytopathogenicity	[PMID: 18707089]
HEL	EC₅₀	0.12 μM Compound: HPMPA	Antiviral activity against PMEDAP-resistant HCMV AD169 clone 4 infected in HEL cells assessed as inhibition of virus-induced cytopathicity Antiviral activity against PMEDAP-resistant HCMV AD169 clone 4 infected in HEL cells assessed as inhibition of virus-induced cytopathicity	[PMID: 19226140]
HEL	EC₅₀	0.17 μM Compound: HPMPA	Antiviral activity against wild type HCMV AD169 infected in HEL cells assessed as inhibition of virus-induced cytopathicity Antiviral activity against wild type HCMV AD169 infected in HEL cells assessed as inhibition of virus-induced cytopathicity	[PMID: 19226140]
HEL	EC₅₀	0.2 μM Compound: HPMPA	Antiviral activity against wild type HCMV Davis infected in HEL cells assessed as inhibition of virus-induced cytopathicity Antiviral activity against wild type HCMV Davis infected in HEL cells assessed as inhibition of virus-induced cytopathicity	[PMID: 19226140]
HEL	EC₅₀	0.91 μg/mL Compound: (S)-HPMPA	Antiviral activity against HCMV 6 with U97 mutation in HEL cells assessed as reduction of virus-induced cytopathogenicity Antiviral activity against HCMV 6 with U97 mutation in HEL cells assessed as reduction of virus-induced cytopathogenicity	[PMID: 18707089]
HEL	EC₅₀	1.2 μg/mL Compound: (S)-HPMPA	Antiviral activity against HCMV 530 with U97 and DNA polymerase mutation in HEL cells assessed as reduction of virus-induced cytopathogenicity Antiviral activity against HCMV 530 with U97 and DNA polymerase mutation in HEL cells assessed as reduction of virus-induced cytopathogenicity	[PMID: 18707089]
HEL	EC₅₀	1.9 μM Compound: HPMPA	Antiviral activity against HPMPA-resistant HCMV AD169 clone 2 mutant infected in HEL cells assessed as inhibition of virus-induced cytopathicity Antiviral activity against HPMPA-resistant HCMV AD169 clone 2 mutant infected in HEL cells assessed as inhibition of virus-induced cytopathicity	[PMID: 19226140]
HEL	EC₅₀	2 μg/mL Compound: (S)-HPMPA	Antiviral activity against ganciclovir-resistant HCMV with DNA polymerase mutant in HEL cells assessed as reduction of virus-induced cytopathogenicity Antiviral activity against ganciclovir-resistant HCMV with DNA polymerase mutant in HEL cells assessed as reduction of virus-induced cytopathogenicity	[PMID: 18707089]
HEL	EC₅₀	2.1 μM Compound: HPMPA	Antiviral activity against cidofovir HCMV AD169 clone 5 infected in human HEL cells assessed as inhibition of virus-induced cytopathicity Antiviral activity against cidofovir HCMV AD169 clone 5 infected in human HEL cells assessed as inhibition of virus-induced cytopathicity	[PMID: 19226140]
HEL	EC₅₀	2.3 μg/mL Compound: (S)-HPMPA	Antiviral activity against HCMV 521 with U97 and DNA polymerase mutation in HEL cells assessed as reduction of virus-induced cytopathogenicity Antiviral activity against HCMV 521 with U97 and DNA polymerase mutation in HEL cells assessed as reduction of virus-induced cytopathogenicity	[PMID: 18707089]
HEL	EC₅₀	3.3 μg/mL Compound: (S)-HPMPA	Antiviral activity against (S)-3-hydroxy-2-phosphonomethoxypropyl cytosine-resistant HCMV with DNA polymerase mutant in HEL cells assessed as reduction of virus-induced cytopathogenicity Antiviral activity against (S)-3-hydroxy-2-phosphonomethoxypropyl cytosine-resistant HCMV with DNA polymerase mutant in HEL cells assessed as reduction of virus-induced cytopathogenicity	[PMID: 18707089]
HEL	EC₅₀	6.2 μg/mL Compound: (S)-HPMPA	Antiviral activity against (S)-3-hydroxy-2-phosphonomethoxypropyl adenine-resistant HCMV with DNA polymerase mutant in HEL cells assessed as reduction of virus-induced cytopathogenicity Antiviral activity against (S)-3-hydroxy-2-phosphonomethoxypropyl adenine-resistant HCMV with DNA polymerase mutant in HEL cells assessed as reduction of virus-induced cytopathogenicity	[PMID: 18707089]
HEL 299	CC₅₀	32 μM Compound: 1b, HPMPA	Cytotoxicity against HEL299 cells after 4 days by Z1 Coulter counting analysis Cytotoxicity against HEL299 cells after 4 days by Z1 Coulter counting analysis	[PMID: 17893157]
HEL 299	EC₅₀	0.5 μM Compound: 1b, HPMPA	Antiviral activity against Camelpox virus CML1 infected in HEL299 cells assessed as inhibition of virus-induced cytopathic effect after 6 days by Giemsa staining Antiviral activity against Camelpox virus CML1 infected in HEL299 cells assessed as inhibition of virus-induced cytopathic effect after 6 days by Giemsa staining	[PMID: 17893157]
HepG2 2.2.15	CC₅₀	>300 μM Compound: (S)-HPMPA	Cytotoxicity against human HepG2(2.2.15) cells after 24 hrs by neutral red assay Cytotoxicity against human HepG2(2.2.15) cells after 24 hrs by neutral red assay	[PMID: 19398648]
HepG2 2.2.15	EC₅₀	1.2 μM Compound: (S)-HPMPA	Antiviral activity against HBV infected in human HepG2(2.2.15) cells assessed as decrease in extracellular viral DNA level after 24 hrs by blot hybridization assay Antiviral activity against HBV infected in human HepG2(2.2.15) cells assessed as decrease in extracellular viral DNA level after 24 hrs by blot hybridization assay	[PMID: 19398648]
HFF	CC₅₀	>289 μM Compound: (S)-HPMPA	Cytotoxicity against HFF cell Cytotoxicity against HFF cell	[PMID: 16539388]
HFF	CC₅₀	>289 μM Compound: (S)-HPMPA	Cytotoxicity against HFF cells after 7 days Cytotoxicity against HFF cells after 7 days	[PMID: 17846137]
HFF	EC₅₀	2.7 μM Compound: (S)-HPMPA	Antiviral activity against Vaccinia virus Copenhagen replication in HFF cells Antiviral activity against Vaccinia virus Copenhagen replication in HFF cells	[PMID: 16539388]
HFF	EC₅₀	2.7 μM Compound: (S)-HPMPA	Antiviral activity against Vaccinia virus Copenhagen in HFF cells assessed as reduction of viral replication after 3 days Antiviral activity against Vaccinia virus Copenhagen in HFF cells assessed as reduction of viral replication after 3 days	[PMID: 17846137]
HFF	EC₅₀	4 μM Compound: (S)-HPMPA	Antiviral activity against Cowpox virus Brighton replication in HFF cells Antiviral activity against Cowpox virus Brighton replication in HFF cells	[PMID: 16539388]
HFF	EC₅₀	4 μM Compound: (S)-HPMPA	Antiviral activity against Cowpox virus Brighton in HFF cells assessed as reduction of viral replication after 3 days Antiviral activity against Cowpox virus Brighton in HFF cells assessed as reduction of viral replication after 3 days	[PMID: 17846137]
HFF	EC₅₀	6.5 μM Compound: (S)-HPMPA	Antiviral activity against Vaccinia virus WR in HFF cells assessed as reduction of viral replication after 3 days Antiviral activity against Vaccinia virus WR in HFF cells assessed as reduction of viral replication after 3 days	[PMID: 17846137]
HFF	IC₅₀	0.41 μM Compound: 1, (S)-HPMPA	Antiviral activity against HCMV Towne infected in HFF cells incubated for 10 days by plaque reduction assay Antiviral activity against HCMV Towne infected in HFF cells incubated for 10 days by plaque reduction assay	[PMID: 21812420]
HFF	IC₅₀	100 μM Compound: 1, (S)-HPMPA	Cytotoxicity against HFF cells after 48 hrs by visual cytotoxicity observation assay Cytotoxicity against HFF cells after 48 hrs by visual cytotoxicity observation assay	[PMID: 21812420]
HFF	IC₅₀	2 μM Compound: 1, (S)-HPMPA	Antiviral activity against Vaccinia virus Copenhagen infected in HFF cells incubated for 3 days by plaque reduction assay Antiviral activity against Vaccinia virus Copenhagen infected in HFF cells incubated for 3 days by plaque reduction assay	[PMID: 21812420]
HFF	IC₅₀	35 μM Compound: 1, (S)-HPMPA	Antiviral activity against HSV1 KOS infected in HFF cells incubated for 3 days by plaque reduction assay Antiviral activity against HSV1 KOS infected in HFF cells incubated for 3 days by plaque reduction assay	[PMID: 21812420]
HFF	IC₅₀	4 μM Compound: 1, (S)-HPMPA	Antiviral activity against Cowpox virus Brighton infected in HFF cells incubated for 3 days by plaque reduction assay Antiviral activity against Cowpox virus Brighton infected in HFF cells incubated for 3 days by plaque reduction assay	[PMID: 21812420]
Huh-7	CC₅₀	>100 μM Compound: (S)-HPMPA	Cytotoxicity against human Huh7.5 cells administered for 3 days measured 24 hrs after last dose by neutral red dye uptake assay Cytotoxicity against human Huh7.5 cells administered for 3 days measured 24 hrs after last dose by neutral red dye uptake assay	[PMID: 19289518]
Huh-7	EC₅₀	>100 μM Compound: (S)-HPMPA	Antiviral activity against HCV1B BM4-5 infected in human Huh7.5 cells assessed as decrease in intracellular viral RNA treated for 3 days measured 24 hrs after last dose by luciferase reporter gene-based blot hybridization Antiviral activity against HCV1B BM4-5 infected in human Huh7.5 cells assessed as decrease in intracellular viral RNA treated for 3 days measured 24 hrs after last dose by luciferase reporter gene-based blot hybridization	[PMID: 19289518]
KB	IC₅₀	>100 μM Compound: 1, (S)-HPMPA	Cytotoxicity against human KB cells after 48 hrs by crystal violet staining based spectrophotometric analysis Cytotoxicity against human KB cells after 48 hrs by crystal violet staining based spectrophotometric analysis	[PMID: 21812420]

In Vitro

(S)-HPMPApp is a good substrate for vaccinia DNA polymerase, readily incorporating into the DNA strand without causing strand termination; instead, it exerts its inhibitory effect by inhibiting 3'-to-5' exonuclease activity and blocking template strand elongation^[1].
(S)-HPMPA (1-100 μg/mL, 24-72 h) can effectively inhibit viral replication in primary rabbit kidney cells^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Molecular Weight

303.21

Formula

C₉H₁₄N₅O₅P

CAS No.

92999-29-6

SMILES

O=P(O)(O)CO[C@H](CO)CN1C2=NC=NC(N)=C2N=C1

Shipping

Room temperature in continental US; may vary elsewhere.

Storage

Please store the product under the recommended conditions in the Certificate of Analysis.

Purity & Documentation

Handling Instructions (2659 KB)

References

[1]. Hostetler KY. Alkoxyalkyl prodrugs of acyclic nucleoside phosphonates enhance oral antiviral activity and reduce toxicity: current state of the art. Antiviral Res. 2009 May;82(2):A84-98. [Content Brief]

[2]. De Clercq E, et al. A novel selective broad-spectrum anti-DNA virus agent. Nature. 1986 Oct 2-8;323(6087):464-7. [Content Brief]

(S)-HPMPA Related Classifications

Infection

Molarity Calculator
Dilution Calculator

The molarity calculator equation

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass		Concentration		Volume		Molecular Weight *
	=		×		×

The dilution calculator equation

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

This equation is commonly abbreviated as: C₁V₁ = C₂V₂

Concentration _(start)	×	Volume _(start)	=	Concentration _(final)	×	Volume _(final)
	×		=		×
C1		V1		C2		V2

Help & FAQs

Do most proteins show cross-species activity?
Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Your Recently Viewed Products:

Product Name

Requested Quantity *

Applicant Name *

Salutation

Email Address *

Phone Number *

Department

Organization Name *

City

State

Country or Region *

Remarks

Product Name

Lot #

Applicant Name *

Email Address *

Phone Number

Department *

Organization Name *

Country or Region *

Remarks

Name
Email *

	Sorry, but the email address you supplied was invalid.

(S)-HPMPA

(S)-HPMPA Related Antibodies

Featured Recommendations

•Related Small Molecules:

•Related Proteins:

View All DNA/RNA Synthesis Isoform Specific Products:

Biological Activity

Purity & Documentation

References

Customer Review

(S)-HPMPA Related Antibodies

(S)-HPMPA Related Classifications

Molarity Calculator

Dilution Calculator

The molarity calculator equation

The dilution calculator equation

Keywords:

Your Recently Viewed Products:

Customer Review

Request for HNMR Report

SAFETY DATA SHEET (SDS)

Request for HNMR Report